<DOC>
	<DOCNO>NCT02836847</DOCNO>
	<brief_summary>The purpose study evaluate feasibility , efficacy safety target therapy accord genomic proteomic profiling combine GEMOX advance recurrent extrahepatic cholangiocarcinoma gallbladder carcinoma .</brief_summary>
	<brief_title>Molecularly Target Therapy With GEMOX Advanced Recurrent Extrahepatic Cholangiocarcinoma Gallbladder Carcinoma</brief_title>
	<detailed_description>Genomic profiling study deoxyribonucleic acid ( DNA ) tumor detect genetic change abnormality . immuno-histochemistry test reveal abnormal activation status signal pathway involve study.These information use recommend target therapy may likely result beneficial response.Patients receive target anti-tumor agent accord result genomic proteomic profiling .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Chinese； Stable vital sign , KPS≥60 ; Patients diagnosis advanced recurrent metastatic extrahepatic cholangiocarcinoma gallbladder carcinoma histopathology cytopathology , suitable radical surgery progress R1 resection palliative surgery ; Adequate fresh tumor tissue genome sequence immunohistochemistry test ; harbor mutation abnormal activation erbb2 receptor tyrosine kinase signal pathway component ; At least one measurable evaluable site disease accord RECIST criterion version 1.1 ; Life expectancy 12 week ; Adequate hepatic , hematologic renal function ( ALT≤10×upper limit normal ( ULN ) , AST≤10×ULN , ChildPugh classification class A B , white blood cells≥3×10^9/L , neutrophils≥1.5×10^9/L , platelets≥80×10^9/L , hemoglobin ≥ 90g/L , creatinine clearance rate≥60ml/min ; Volunteer study , write informed consent good Patient compliance ; Female patient childbearing potential mate agree avoid pregnancy . Have receive following treatment study : 1 . Antitumor molecular target therapy ; antitumor chemotherapy 6 month ; 2. lesion treated irradiation ; 3. participate therapeutic interventional clinical trial . Have central nervous system metastasis ; History malignancy except carcinoma insitu uterine cervix , cure basal cell carcinoma skin malignancies 5 year ; Have symptomatic ascites need treatment ; Have serious concurrent illness include , limit 1. uncontrolled congestive heart failure ( NYHA classification grade III IV ) , unstable angina pectoris , unstable cardiac arrhythmia , uncontrolled moderate serious hypertension ( systolic blood pressure &gt; 21.3 Kpa diastolic blood pressure &gt; 13.3 Kpa ) ; 2. ongoing active serious infection ; 3. uncontrolled diabetes mellitus ; 4. psychiatric illness potentially hamper ability willingly give write informed consent compliance study protocol ; 5 . HIV infection ; 6. serious illness consider suitable study investigator . allergic contraindication target medicine involve study , gemcitabine oxaliplatin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>